April 26, 2017
Article
After eight years with no new treatments for ovarian cancer, PARP inhibitors and anti-angiogenics are benefiting patients.
Healer, Mentor and Leader
Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models
FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors
Crafting an Individual Treatment Plan for Patients With Prostate Cancer